Scarica l'app Stockscreener
0.6621
9.94%
-0.0731
Dopo l'orario di chiusura:
.66
-0.0021
-0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
Stock Market Movers Today • Top Gainers & Losers - Benzinga
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition - Star Local Media
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa Sells 74,773 Shares - MarketBeat
Mark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock - MarketBeat
Insider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells 22,258 Shares of Stock - MarketBeat
X4 Pharmaceuticals CFO Mostafa Adam S. sells $33,946 in stock - MSN
x4 pharmaceuticals CEO sells shares worth $34,718 By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals COO Mary DiBiase sells $10,094 in stock By Investing.com - Investing.com Nigeria
x4 Pharmaceuticals CCO Mark Baldry sells $13,241 in stock - Investing.com
x4 Pharmaceuticals chief commercial officer sells $13,241 in stock - Investing.com
X4 Pharmaceuticals' chief medical officer sells $5,284 in stock - Investing.com
x4 pharmaceuticals CEO sells shares worth $34,718 - Investing.com
x4 Pharmaceuticals CCO Mark Baldry sells $13,241 in stock By Investing.com - Investing.com UK
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixaforlicenced to Norgine for commercialisation in Europe. - Yahoo Finance
X4 Pharma stock gains as lead drug under EU review (XFOR) - Seeking Alpha
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome - Yahoo Finance
Barclays PLC Buys 183,861 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Quantisnow
January 2025's Top US Penny Stocks To Consider - Simply Wall St
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price - Simply Wall St
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
EVP Research Swayze Eric converted options into 19,160 shares and sold $235,678 worth of shares (7,176 units at $32.84), increasing direct ownership by 35% to 45,670 units (SEC Form 4) - Quantisnow
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
X4 Pharmaceuticals (NASDAQ:XFOR) Earns Buy Rating from HC Wainwright - Defense World
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - Scrip
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine - Research Tree
X4 Pharmaceuticals (NASDAQ:XFOR) Receives Buy Rating from HC Wainwright - MarketBeat
Jane Street Group LLC Increases Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
X4 Pharmaceuticals Partners with Norgine for Mavorixafor Expansion - TipRanks
X4 Pharmaceuticals, Inc. and Norgine Pharma UK Limited Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - Marketscreener.com
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - Yahoo Finance
StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
Brookline Capital Management Estimates XFOR FY2024 Earnings - Defense World
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PR Newswire
Brokers Set Expectations for XFOR FY2024 Earnings - MarketBeat
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Fragile X Syndrome Clinical and Non-Clinical Studies, Key - openPR
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Geode Capital Management LLC Trims Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Jagsonpal Pharmaceuticals record date for 1:2.5 stock split today - The Economic Times
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - Quantisnow
Chief Operating Officer Mancini Marianna was granted 66,200 shares and sold $2,317,599 worth of shares (54,215 units at $42.75), increasing direct ownership by 3% to 374,134 units (SEC Form 4) - Quantisnow
Chief Financial Officer Zante Greg sold $2,150,595 worth of shares (50,309 units at $42.75) and was granted 66,200 shares, increasing direct ownership by 11% to 165,259 units (SEC Form 4) - Quantisnow
SEC Form 4 filed by Director Macartney Lawson - Quantisnow
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations - Star Local Media
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program - Yahoo Finance
Prescription Drug Costs | Pros, Cons, Debate, Arguments, Economy, Laws, Government, & Regulation - Britannica
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals Inc (NASDAQ: XFOR): An Enticing Stock To Watch - Stocks Register
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Chicago Star Media
Exciting Hire at Terns Pharma! New Employee Receives Special Stock Grant! - Jomfruland.net
Telangana: Medicines worth Rs 2 crore seized - Medical Dialogues
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Acquired by State Street Corp - Defense World
Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com - Defense World
Stifel Financial Corp Sells 41,819 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Lithium Americas Corp. (NYSE:LAC) Shares Sold by Stifel Financial Corp - Defense World
Definitive Healthcare Corp. (NASDAQ:DH) Shares Sold by Stifel Financial Corp - Defense World
Stifel Financial Corp Reduces Stock Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) - Defense World
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Business Wire
Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4) - Quantisnow
How To Check Senores Pharmaceuticals IPO Allotment Status? Find Latest GMP, Listing Date And More - NDTV Profit
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - Simply Wall St
Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.com - Defense World
Senores Pharmaceuticals IPO oversubscribed 93.69 times; check allotment and listing details - Zee Business
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):